Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trialsNonhlanhla N. Mkhize, Lynn Morris, Tandile Modise et al.|PLoS Pathogens|2023Cited by 57
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Bethany Coomes, Christopher B. Hurt et al.|The Lancet HIV|2024Cited by 12
Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trialsNyaradzo Mgodi, Allan C. deCamp, John Hural et al.|UNC Libraries|2023Cited by 0
Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisitionJoseph Makhema, A. Eaton, Wang Yao Feng et al.|UNC Libraries|2023Cited by 0